BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 32285217)

  • 1. External validation of the "optimal PSA follow-up schedule after radical prostatectomy" in a new cohort.
    Yanai Y; Matsumoto K; Kosaka T; Takeda T; Tanaka N; Morita S; Mizuno R; Shinojima T; Asanuma H; Oya M
    Int J Clin Oncol; 2020 Jul; 25(7):1393-1397. PubMed ID: 32285217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of the optimal follow-up schedule after radical prostatectomy.
    Matsumoto K; Niwa N; Hattori S; Takeda T; Morita S; Kosaka T; Mizuno R; Shinojima T; Kikuchi E; Asanuma H; Oya M
    Urol Oncol; 2018 Jul; 36(7):341.e9-341.e14. PubMed ID: 29730065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
    Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of schedules for optimal prostate-specific antigen monitoring after radical prostatectomy.
    Blas L; Shiota M; Tanegashima T; Tsukahara S; Ueda S; Mutaguchi J; Goto S; Kobayashi S; Matsumoto T; Inokuchi J; Eto M
    Int J Urol; 2024 Apr; 31(4):404-408. PubMed ID: 38154806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence.
    Skove SL; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Moreira DM; Freedland SJ
    Urology; 2017 Oct; 108():129-134. PubMed ID: 28735016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [-2]proPSA versus ultrasensitive PSA fluctuations over time in the first year from radical prostatectomy, in an high-risk prostate cancer population: A first report.
    De Luca S; Passera R; Sottile A; Fiori C; Scarpa RM; Porpiglia F
    BMC Urol; 2016 Mar; 16():14. PubMed ID: 27013515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome.
    Vesely S; Jarolim L; Schmidt M; Minarik I; Dusek P; Babjuk M
    World J Urol; 2013 Apr; 31(2):299-304. PubMed ID: 22684375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen.
    Greenberg SA; Washington SL; Lonergan PE; Cowan JE; Baskin AS; Nguyen HG; Odisho AY; Simko JP; Carroll PR
    J Urol; 2021 Sep; 206(3):706-714. PubMed ID: 33905262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
    Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
    J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen measured 3 months after radical prostatectomy as a new predictor of biochemical recurrence.
    Inoue H; Nishimura K; Yamaguchi S; Nonomura N; Hara T
    Int J Clin Oncol; 2015 Feb; 20(1):171-5. PubMed ID: 24652165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The factors predicting biochemical recurrence in patients with radical prostatectomy.
    Koca O; Ün S; Türk H; Zorlu F
    Arch Ital Urol Androl; 2016 Jan; 87(4):270-5. PubMed ID: 26766796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
    Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
    Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
    O'Brien MF; Cronin AM; Fearn PA; Smith B; Stasi J; Guillonneau B; Scardino PT; Eastham JA; Vickers AJ; Lilja H
    J Clin Oncol; 2009 Aug; 27(22):3591-7. PubMed ID: 19506163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.
    Mir MC; Li J; Klink JC; Kattan MW; Klein EA; Stephenson AJ
    Eur Urol; 2014 Aug; 66(2):204-10. PubMed ID: 24007712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of time to undetectable prostate-specific antigen in patients with positive surgical margins following radical prostatectomy.
    Koo KC; Tuliao P; Komninos C; Choi YD; Chung BH; Hong SJ; Jee SH; Rha KH
    Ann Surg Oncol; 2015 Feb; 22(2):693-700. PubMed ID: 25190131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy.
    Røder MA; Berg KD; Loft MD; Thomsen FB; Ferrari M; Kurbegovic S; Rytgaard HC; Gruschy L; Brasso K; Gerds TA; Kjær A; Brooks JD; Iversen P
    Eur Urol Focus; 2018 Apr; 4(3):360-368. PubMed ID: 28753827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database.
    Ho T; Gerber L; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    Eur Urol; 2012 Nov; 62(5):910-6. PubMed ID: 22921964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy.
    Gandaglia G; Ploussard G; Valerio M; Marra G; Moschini M; Martini A; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Afferi L; Rakauskas A; Gontero P; Mattei A; Montorsi F; Briganti A
    Eur Urol Oncol; 2020 Dec; 3(6):739-747. PubMed ID: 32847747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer.
    Song C; Park S; Park J; Shim M; Kim A; Jeong IG; Hong JH; Kim CS; Ahn H
    Prostate; 2015 Feb; 75(2):211-7. PubMed ID: 25327522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.